Stephen P. Robertson - 18 May 2026 Form 4 Insider Report for Aurinia Pharmaceuticals Inc. (AUPH)

Reporting relationship: Chief Legal Officer
Issuer ticker: AUPH
Reported as of: 18 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 20 May 2026, 17:05:22 UTC
Prior SEC filing: 03 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Stephen P. Robertson

Key filing fact

Stephen P. Robertson filed Form 4 for Aurinia Pharmaceuticals Inc. (AUPH) on 20 May 2026.

Key facts

This page summarizes Stephen P. Robertson's Form 4 filing for Aurinia Pharmaceuticals Inc. (AUPH).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 20 May 2026, 17:05.

Change

Previous filing in this sequence was filed on 03 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001837798 Primary reporting owner

Robertson Stephen P.

Relationship: Chief Legal Officer
Address: #140, 14315 - 118 AVENUE, EDMONTON, ALBERTA, CANADA
Signature: /s/ Stephen P. Robertson
Signature date: 20 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AUPH transaction

Common Stock

Award

Transaction value
Shares: +115,541
Change %: +23%
Price: $0.000000^*
Shares after: 621,402
Date: 18 May 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Each performance stock unit ("PSU") represents a contingent right to receive one common share of the Issuer. 115,541 PSUs vest in two tranches at the three and five year anniversary date of grant if the Issuer's common shares achieve target prices that represent significant increases from the share price on date of grant before the respective vesting date.